Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siLXN
- Development stage
- Preclinical
- Lead developer
- Yonsei University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siLXN is a small interfering RNA (siRNA) designed to silence the expression of Latexin (LXN), a protein identified as a prognostic marker in pancreatic cancer. Developed for research purposes by investigators at Yonsei University, siLXN is utilized to investigate the functional role of LXN in tumor progression. Experimental data from patient-derived cancer models, including conditionally reprogrammed cell (CRC) cultures and 3D organoids, indicate that siLXN-mediated knockdown of LXN leads to a reduction in Akt/mTOR signaling and inhibits the proliferation of pancreatic cancer cells. While high LXN expression is associated with improved overall survival in patients, siLXN serves as a critical tool for validating the molecular mechanisms and therapeutic potential of targeting the LXN pathway in oncology.
- Other names
- latexin siRNAsiRNA targeting LXN
02
Targets
AGO2 (Argonaute RISC catalytic component 2)LXN (Latexin)
Beyond the preview
Go deeper on siLXN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siLXN.